Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GigAINt secukinumab trial in new-onset giant cell arteritis
2021-002622-24Phase 3Active
- Sponsor
- Novartis
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in giant cell arteritis (GCA) comparing Secukinumab + glucocorticoid taper with Placebo + glucocorticoid taper (2 arms). Primary endpoint: Time to first GCA clinical relapse. Started Mar 2022; status: active.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2021-002622-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002622-24.